AU2009320350B2 - Methods and compositions for inhibiting Clostridium difficile spore germination and outgrowth - Google Patents

Methods and compositions for inhibiting Clostridium difficile spore germination and outgrowth Download PDF

Info

Publication number
AU2009320350B2
AU2009320350B2 AU2009320350A AU2009320350A AU2009320350B2 AU 2009320350 B2 AU2009320350 B2 AU 2009320350B2 AU 2009320350 A AU2009320350 A AU 2009320350A AU 2009320350 A AU2009320350 A AU 2009320350A AU 2009320350 B2 AU2009320350 B2 AU 2009320350B2
Authority
AU
Australia
Prior art keywords
difficile
group
subject
associated disease
con
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2009320350A
Other languages
English (en)
Other versions
AU2009320350A1 (en
Inventor
Abraham L. Sonenshein
Joseph Sorg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tufts University
Original Assignee
Tufts University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tufts University filed Critical Tufts University
Publication of AU2009320350A1 publication Critical patent/AU2009320350A1/en
Application granted granted Critical
Publication of AU2009320350B2 publication Critical patent/AU2009320350B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AU2009320350A 2008-11-03 2009-11-02 Methods and compositions for inhibiting Clostridium difficile spore germination and outgrowth Ceased AU2009320350B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US11074708P 2008-11-03 2008-11-03
US61/110,747 2008-11-03
US12283508P 2008-12-16 2008-12-16
US61/122,835 2008-12-16
US15013609P 2009-02-05 2009-02-05
US61/150,136 2009-02-05
PCT/US2009/005929 WO2010062369A2 (en) 2008-11-03 2009-11-02 Methods and compositions for inhibiting clostridium difficile spore germination and outgrowth

Publications (2)

Publication Number Publication Date
AU2009320350A1 AU2009320350A1 (en) 2010-06-03
AU2009320350B2 true AU2009320350B2 (en) 2015-09-24

Family

ID=42226300

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009320350A Ceased AU2009320350B2 (en) 2008-11-03 2009-11-02 Methods and compositions for inhibiting Clostridium difficile spore germination and outgrowth

Country Status (6)

Country Link
US (2) US9340569B2 (enExample)
EP (1) EP2367839A4 (enExample)
JP (1) JP5620392B2 (enExample)
AU (1) AU2009320350B2 (enExample)
CA (1) CA2779413A1 (enExample)
WO (1) WO2010062369A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9079935B2 (en) 2012-08-13 2015-07-14 The Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Las Vegas Reducing risk of contracting Clostridium-difficile associated disease
MX2015006491A (es) 2012-11-23 2015-12-03 Seres Health Inc Composiciones bacterianas sinergicas y metodos de produccion y uso de las mismas.
EP2951283A4 (en) 2013-02-04 2017-01-25 Seres Therapeutics, Inc. Compositions and methods
MX369877B (es) 2013-02-04 2019-11-25 Seres Therapeutics Inc Composiciones y metodos.
JP2016519664A (ja) 2013-03-15 2016-07-07 セレス セラピューティクス インコーポレイテッド ネットワークを基にした微生物組成物及び方法
WO2015076788A1 (en) 2013-11-19 2015-05-28 The Texas A&M University System Muricholic acid-based compounds as inhibitors of clostridium difficile spore germination
MX367109B (es) 2013-11-25 2019-08-05 Seres Therapeutics Inc Composiciones bacterianas sinergicas y sus metodos de produccion y usos.
US9956282B2 (en) 2013-12-16 2018-05-01 Seres Therapeutics, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
EP3146065B1 (en) 2014-05-19 2024-11-13 Memorial Sloan Kettering Cancer Center Methods and compositions for reducing clostridium difficile infection
GB201421071D0 (en) * 2014-11-27 2015-01-14 Univ Aston Compound for treating clostridium difficile
US20180000793A1 (en) 2015-02-06 2018-01-04 Ernesto Abel-Santos Inhibiting Germination of Clostridium Perfringens Spores to Reduce Necrotic Enteritis
KR20180093903A (ko) 2015-11-03 2018-08-22 더 브리검 앤드 우먼즈 하스피털, 인크. 음식 알레르기의 치료 및/또는 예방을 위한 치료용 미생물총
MY190858A (en) * 2016-04-05 2022-05-12 Nch Corp Nutrient rich germinant composition and spore incubation method
BR112020002992A2 (pt) 2017-08-14 2020-08-18 Seres Therapeutics, Inc. composições e métodos para tratamento de doença colestática
KR102323783B1 (ko) * 2017-09-22 2021-11-09 주식회사 고바이오랩 클로스트리디움 디피실레(Clostridium difficile) 성장 억제효과를 갖는 클로스트리디움 신덴스 균주
JP2021501185A (ja) 2017-10-30 2021-01-14 セレス セラピューティクス インコーポレイテッド 抗生物質耐性を処置するための組成物及び方法
AR115921A1 (es) 2018-08-10 2021-03-10 Phenex Pharmaceuticals Ag Ácido isolitocólico o ácido isoalolitocólico y derivados deuterados de los mismos para prevenir y tratar enfermedades asociadas a clostridium difficile
CA3109900A1 (en) 2018-08-17 2020-02-20 Universidad Andres Bello Method and pharmacological composition for the prevention of recurrent infections caused by clostridium difficile
WO2020260558A1 (en) 2019-06-27 2020-12-30 Phenex Pharmaceuticals Ag 3-modified iso-/isoallo-lithocholic acid derivatives or their homo-analogs for preventing and treating clostridioides difficile-associated diseases
US20230146782A1 (en) * 2019-08-06 2023-05-11 Du Jessica Xinyun Deoxycholic acid compounds, pharmaceutical compositions and uses thereof
EP4092103A4 (en) * 2020-01-16 2024-05-15 Keio University PROCESS FOR PRODUCING BILE ACIDS
WO2021163212A1 (en) 2020-02-10 2021-08-19 Native Microbials, Inc. Microbial compositions and methods of use for canine enteropathy and dysbiosis
US12220421B2 (en) 2021-09-09 2025-02-11 The Boards Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Las Inhibitors of C. difficile spore germination
WO2023079335A1 (en) 2021-11-03 2023-05-11 Universidad Andrés Bello Composition based on nystatin and vancomycin nanoparticles for the treatment of clostridioides difficile infection and prevention of recurrence
US20250002450A1 (en) 2021-12-10 2025-01-02 Universidade Do Porto Cationic steroid compounds, method of obtaining thereof, formulations comprising thereof and their uses
CN120905091A (zh) * 2025-09-30 2025-11-07 北京常友生物科技有限公司 大肠埃希氏菌yc49及其协同拟杆菌在抑制艰难梭菌中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326364B1 (en) * 1999-02-08 2001-12-04 Cedars-Sinai Medical Center Use of 5-aminosalicylates as antimicrobial agents
US20080254010A1 (en) * 2007-03-12 2008-10-16 Joseph Myron Sasser Controlling Clostridium difficile-Associated Disease in the Gastrointestinal Tract

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3708510A (en) * 1970-09-03 1973-01-02 Merck & Co Inc Amides of cholanic acid,cholenic acid,and choladienic acid
JPS62175497A (ja) 1986-01-28 1987-08-01 Wakunaga Pharmaceut Co Ltd 胆汁酸誘導体およびその製造法
JPH0749438B2 (ja) * 1990-10-31 1995-05-31 東京田辺製薬株式会社 タウリン抱合型胆汁酸の精製方法
DE19645044A1 (de) * 1996-10-31 1998-05-07 Falk Pharma Gmbh Verwendung von Ursodeoxycholsäure zur topischen Behandlung von Entzündungserkrankungen der Schleimhäute
IL123998A (en) 1998-04-08 2004-09-27 Galmed Int Ltd Conjugates of bile salts and pharmaceutical preparations containing them
US7247299B2 (en) 2002-11-27 2007-07-24 Kemin Industries, Inc. Antimicrobial compounds from Bacillus subtilis for use against animal and human pathogens
EP2001897A2 (en) * 2006-03-22 2008-12-17 Syndexa Pharmaceuticals Corporation Compounds and methods for treatment of disorders associated with er stress

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326364B1 (en) * 1999-02-08 2001-12-04 Cedars-Sinai Medical Center Use of 5-aminosalicylates as antimicrobial agents
US20080254010A1 (en) * 2007-03-12 2008-10-16 Joseph Myron Sasser Controlling Clostridium difficile-Associated Disease in the Gastrointestinal Tract

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Murphy, G.M. et al, Biochemical Journal, 1972, vol. 129, pp. 491-494 *
Quistad, G.B. et al, Nature, 1982, vol. 296, pp. 462-464 *
Ridlon, J.M. et al, J. Lipid Res., 2006, vol. 47, pp. 241-259 *
Sorg et al, J. Bacteriol., 2008, vol. 190(7), pp. 2505-2512 *

Also Published As

Publication number Publication date
US20170056419A1 (en) 2017-03-02
JP2012507521A (ja) 2012-03-29
WO2010062369A3 (en) 2010-10-14
US9340569B2 (en) 2016-05-17
JP5620392B2 (ja) 2014-11-05
WO2010062369A2 (en) 2010-06-03
EP2367839A4 (en) 2012-07-04
AU2009320350A1 (en) 2010-06-03
EP2367839A2 (en) 2011-09-28
US20110280847A1 (en) 2011-11-17
CA2779413A1 (en) 2010-06-03

Similar Documents

Publication Publication Date Title
US9340569B2 (en) Methods and compositions for inhibiting clostridium difficile spore germination and outgrowth
USRE49949E1 (en) Reducing risk of contracting clostridium-difficile associated disease
JP7602513B2 (ja) オキシステロールおよびそれらの使用の方法
JP2021046444A (ja) オキシステロールおよびそれらの使用の方法
WO2017142895A1 (en) Compositions and methods for treating clostridium associated diseases
JP2019510051A (ja) オキシステロールおよびその使用方法
CN110878113B (zh) 一种具有抗菌活性的胆酸衍生物及其药用组合物
US10766855B2 (en) Hydroxamate triterpenoid derivatives
WO2022169909A2 (en) Methods and compositions for treating disorders associated with bile acids
Sharma et al. 5, 6-Fused heterocycle cholate derivatives as spore germination inhibitors of Clostridioides difficile
WO2020260558A1 (en) 3-modified iso-/isoallo-lithocholic acid derivatives or their homo-analogs for preventing and treating clostridioides difficile-associated diseases
JP2015143209A (ja) ピリドンカルボン酸系抗菌薬のアルコキシカルボニルヘミアセタール型エステルプロドラッグ
WO2015076788A1 (en) Muricholic acid-based compounds as inhibitors of clostridium difficile spore germination
Gérard Gastrointestinal tract: Microbial metabolism of steroids
US20210323995A1 (en) Isolithocholic acid or isoallolithocholic acid and deuterated derivatives thereof for preventing and treating clostridium difficile-associated diseases
Sharma et al. Studies on the Importance of the 7α-, and 12α-hydroxyl groups of N-Aryl-3α, 7α, 12α-trihydroxy-5β-cholan-24-amides on their Antigermination Activity Against a Hypervirulent Strain of Clostridioides (Clostridium) difficile
TW202502306A (zh) Gpx4抑制劑與抗衰老化合物及其用途
JP2025503418A (ja) 脂質及びステロイド代謝を調節するために胆汁酸を改変するための組成物及び方法
US10011589B2 (en) Treatments for gastrointestinal conditions
WO2026093429A1 (en) Triazolo compounds for treatment of bile acid diarrhea and autoimmune enteropathy
WO2017035288A1 (en) Composition and method for prevention, mitigation or treatment of an enteropathogenic bacterial infection
CN117897148A (zh) 不饱和羟肟酸衍生物及其用于治疗和预防氨相关疾病或病症的用途
Hird Synthesis of a molecularly tethered dual function germinant and antimicrobial agent

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired